GMAB
BuyPremium GrowerFLAGGenmab A/S · Healthcare · Denmark · $20.4B · Avg Vol: $87M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Insufficient evidence for a screen-pass. Genmab A/S: fails the quant gate on value (Q61/V44/M53; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT GENMAB A/S
Read
Genmab A/S is a leading international biotechnology company focused on the research and development of differentiated antibody therapeutics for the treatment of cancer, utilizing its proprietary antibody discovery platforms. The company's competitive moat is built upon its innovative R&D pipeline, deep scientific expertise in oncology, and strategic collaborations with global pharmaceutical partners for accelerating drug development and market access. Genmab is recognized for its significant contributions to antibody-based cancer therapies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 2.1B | 2.4B | 3.1B | 3.7B | 21.2% | 4.1B | 4.6B | 5.3B | 19.5% |
| EPS | 0.70 | 0.13 | 0.10 | 0.18 | 0.16 | -31.4% | 1.26 | 0.10 | 0.14 | -5.3% |
| Shares | — | 613.9M | 613.9M | 613.9M | 613.9M | 0.0% | 614.9M | — | — | — |
| Debt | — | 85.9M | 114.0M | 144.0M | 5.4B | 298.2% | 5.3B | — | — | — |
| Equity | — | 3.9B | 4.7B | 5.1B | 5.8B | 14.2% | — | — | — | — |
| Op CF | — | 563.0M | 1.1B | 1.1B | 1.2B | 28.2% | 891.0M | — | — | — |
| Inv CF | — | -397.4M | -185.0M | -1.4B | -5.6B | — | — | — | — | — |
| Fin CF | — | -113.6M | -89.0M | -566.0M | 4.8B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GMAB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GMAB | Genmab A/S(you) | $20.4B | 65 | Buy |
| ASND | Ascendis Pharma A/S | $16.3B | 54 | Hold |
| ALK-B.CO | ALK-Abelló A/S | $7.2B | 65 | Buy |
| ZEAL.CO | Zealand Pharma A/S | $3.3B | 94 | Strong Buy |
| BAVA.CO | Bavarian Nordic A/S | $2.5B | 98 | Strong Buy |
| GUBRA.CO | Gubra A/S | $990M | 33 | Sell |
| CBHD.DE | Coloplast A/S | $16.1B | 70 | Buy |
| SANION.ST | Saniona AB (publ) | $167M | 80 | Strong Buy |
| DEMANT.CO | Demant A/S | $9.3B | 89 | Strong Buy |
| AMBU-B.CO | Ambu A/S | $2.9B | 60 | Hold |
Peer medians: ROE 18.5% · P/E 10.8x · Gross margin 82.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.